Federal Circuit rules against J&J in Zytiga dispute
16-05-2019
CIPhotos / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has invalidated a Johnson & Johnson (J&J) patent covering its prostate cancer drug Zytiga (abiraterone acetate).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Johnson & Johnson, cancer, generics, Zytiga, PTAB, Patent Trial and Appeal Board, inter partes review
